Top Markets
Coin of the day
PHAXIAM Therapeutics S.A. PHAXIAM Therapeutics S.A.

PHAXIAM Therapeutics S.A.

PHXM
株式のランク #39465
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
株価
$0.11725176
最終同期: 2025-07-14
時価総額
$481.50K
変化(1日)
-0.20%
変化(1年)
0.00%
FR
取引 PHAXIAM Therapeutics S.A. (PHXM)

カテゴリー

PHAXIAM Therapeutics S.A.(PHXM)の収益
Jun 2024 時点の収益 TTM: $2.30M
PHAXIAM Therapeutics S.A. の最新の財務報告によると、現在の収益 (TTM) は $2.30M です。2022 年には $7.13M の収益があり、これは 2021 年の $4.75M と比較して 増加 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
PHAXIAM Therapeutics S.A. の収益履歴(2016 ~ 2026)
各年末の収益
収益 変化
2026 (TTM) $2.30M 56.82%
2023 $1.47M -79.44%
2022 $7.13M 50.00%
2021 $4.75M 4.97%
2020 $4.53M -23.61%
2019 $5.93M 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
2016 0.00 0.00%
同業他社の収益
企業 収益 収益の差
$12.62B 549,098.33%
US
$6.02B 261,845.69%
NL
- -
CH
- -
KR
$10.11B 439,752.28%
BE